Quanterix Chief Medical Officer Appointed to Mammogen Leadership Council
Dr. Yuri Fesko, Chief Medical Officer of Quanterix, has been appointed as a founding member of Mammogen's newly formed Leadership Council.
Stocks · News reference
Quanterix (NASDAQ:QTRX) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Dr. Yuri Fesko, Chief Medical Officer of Quanterix, has been appointed as a founding member of Mammogen's newly formed Leadership Council.
Filed: 2026-11-18 AccNo: 0001503274-26-000051 Size: 162 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Quanterix Corporation has entered into an exclusive distribution agreement with Sherman Abrams Laboratory to provide its LucentAD® Complete blood tests to patients in New Jersey and the surrounding region.
Quanterix Corporation has signed a Memorandum of Understanding (MOU) with ALZAI Health Corp. to explore collaboration opportunities for improving the early identification and assessment of Alzheimer's disease.
TD Cowen analyst Daniel Brennan has maintained a hold rating on Quanterix Corporation while increasing the price target from $3.50 to $4.00.